To investigate the peri-operative and oncological outcomes of robot-assisted radical prostatectomy (RARP) in patients with oligometastatic prostate cancer (PCa).
Introduction
Oligometastatic cancer, in which patients have a limited number of metastatic lesions and/or sites, is considered a unique clinical condition that exists between localized cancer and widespread systemic disease [1] . It has been proposed that oligometastatic cancer can be controlled or even cured by local treatment such as surgery or radiotherapy (RT) [1, 2] . In support of this proposal, several studies have shown that decreasing primary tumour burden through cytoreductive or radical surgery improves survival in patients with various cancers including colorectal, lung and RCC [3] [4] [5] .
Historically, androgen deprivation therapy (ADT) has been the standard treatment option for metastatic prostate cancer (PCa). Radical prostatectomy (RP) has been offered only with the intention to cure localized or locally advanced disease, including PCa with lymph node involvement. Recently, however, a few studies have reported that treatment of the primary tumour might provide a survival benefit to patients with PCa who have metastases [6, 7] ; thus, there is a growing interest in the role of local treatment in oligometastatic PCa. Unfortunately, studies examining the use of RP and RT for treating oligometastatic PCa are limited [7] [8] [9] [10] . feedback using robot-assisted surgery, recent studies have suggested that RARP is safe and effective even in this setting [12] [13] [14] . Considering these reports, we analysed the perioperative outcomes of RARP in patients diagnosed with oligometastatic PCa at a single, high-volume centre. Moreover, we assessed the oncological outcomes after treatment with RARP vs ADT in these patients.
Patients and Methods

Patient Population
We retrospectively reviewed the records of 91 patients treated with RARP or ADT as initial therapies for oligometastatic PCa between 2005 and 2015 at our institution. Oligometastatic disease was defined as the presence of five or fewer hot spots apparent by bone scan, without the presence of visceral metastases at the preoperative imaging evaluation [8, 15] . After the exclusion of 12 patients with incomplete clinicopathological or followup data, 79 men with oligometastatic PCa were included in the final analysis. Of these 79 patients, 38 were treated with RARP (RARP group), and 41 were treated with ADT without local therapy until progression (ADT group). RARP was performed by two high-volume surgeons (annual volume > 200 cases). Patients in the ADT group were treated with bicalutamide 50 mg once daily in combination with a LHRH analogue (goserelin) injection on a quarterly basis. The decision as to treatment method was left to the physician's clinical judgement after discussion with the patient regarding the probable benefits and adverse effects of each treatment. Prior to treatment, all patients were evaluated with chest X-ray, whole-body bone scan, and abdominal-pelvic CT or MRI.
Patient Characteristics
Clinicopathological characteristics, including age, PSA level at the time of biopsy, Charlson comorbidity index, biopsy Gleason score, and clinical T and N stage were obtained through a review of medical records at our institution. The TNM stage was determined according to the 7th edition of the American Joint Committee on Cancer TNM staging system [16] .
Pelvic lymphadenectomy and RARP were performed as previously described [17, 18] . The extended lymph node dissection template comprised the external iliac, obturator, internal iliac and common iliac up to the ureteric crossing. Operating time, estimated blood loss, blood transfusions, length of hospital stay, catheter maintenance period, reoperation, readmission, postoperative complications (stratified according to the Clavien-Dindo classification system), final pathology of the RARP specimen, and use of postoperative therapy were evaluated.
Follow-Up
Postoperative PSA follow-up analysis was performed monthly for the first 6 months, every 3 months through the second year, and semi-annually thereafter. If a patient showed symptomatic progression or an increase in PSA levels, followup imaging studies, including bone scans, were performed. Progression-free survival (PFS) was defined as the time from diagnosis to disease progression or relapse, or to death as a result of any cause. Cancer-specific survival (CSS) was defined as the time from diagnosis to death from PCa. Data regarding mortality and cause of death were obtained from medical records in the Cancer Registry Centre database at our institution.
Statistical Analysis
We compared clinical and pathological characteristics between groups using Mann-Whitney U-tests for continuous data and chi-squared tests for dichotomous variables. We used the Kaplan-Meier method with log-rank tests to estimate and compare oncological outcomes between groups. Cox proportional hazard models were used to investigate associations between variables and the risks of oncological outcomes. All clinical covariates were included in the univariate and multivariate models. All analyses were conducted using SPSS 18.0 software (SPSS, Inc., Chicago, IL, USA). Comparisons with P < 0.05 were considered statistically significant.
Good Clinical Practice Protocols
This study was performed in agreement with the applicable laws and regulations, good clinical practices, and ethical principles described in the Declaration of Helsinki. The institutional review board of the hospital approved thie study protocol (approval number: 4-2016-0999).
Results
For the entire cohort, the median follow-up time was 40 (interquartile range [IQR] 28-58) months. The patients' demographic characteristics are summarized in Table 1 . The patients in the RARP group were younger than those in the ADT group (P < 0.001). There were no significant differences in PSA levels, Charlson comorbidity indices, biopsy Gleason scores, and clinical stage classifications between the two groups. Table 2 were 5 (4-7) days and 10 (10-12) days, respectively. Three patients (7.9%) received blood transfusions, and two patients (5.3%) experienced grade III postoperative complications. One patient (2.6%) underwent a reoperation on the following day as a result of rectal injury. Thirty-five patients (92.1%) received an extended lymph node dissection. The median (IQR) number of lymph nodes harvested was 21 (18) (19) (20) (21) (22) (23) (24) . Eleven patients (28.9%) had lymph node metastasis and 30 patients (78.9%) had positive surgical margins. Adjuvant ADT was administered to 28 patients (73.7%). Finally, seven (18.4%) and 15 (39.5%) patients received adjuvant and salvage RT, respectively. Table 3 shows urinary complications requiring percutaneous or surgical intervention in each treatment group. In the RARP group, there were no urinary tract complications attributable to disease progression. By contrast, of the 41 patients in the ADT group, 11 (26.8%) required interventions secondary to disease progression. Of these 11 patients, six (14.6%) and two (4.9%) underwent TURP and suprapubic cystostomy for BOO, respectively, two (4.9%) underwent percutaneous nephrostomy because of ureteric obstruction, and one (2.4%) required cystoscopic evacuation for bladder clot retention.
Among all patients, 45 (57.0%) experienced radiographic progression. Of these 45 patients, 19 (50.0%) were from the RARP group and 26 (63.4%) were from the ADT group. Kaplan-Meier analyses showed that PFS was longer in patients in the RARP group compared with those in the ADT group (P = 0.008), and the median PFS was 75 months in the RARP group compared with 28 months in the ADT group (Fig. 1) . Furthermore, univariate and multivariate Cox regression analyses showed that a biopsy Gleason score ≥9 (hazard ratio [HR] 2.548, 95% CI 1.362À4.767; P = 0.003) ADT, androgen deprivation therapy; IQR, interquartile range; RARP, robot-assisted radical prostatectomy. and RARP (HR 0.388, 95% CI 0.206À0.731; P = 0.003) were independent prognostic factors for PFS (Table 4 ).
In the entire cohort, 24 patients (30.4%) died during follow-up as a result of PCa. Of these 24 patients, seven (8.9%) were from the RARP group and 17 (21.5%) were from the ADT group. Kaplan-Meier analyses showed that CSS was longer in patients in the RARP group than in the ADT group (P = 0.002). The median CSS was not reached in the RARP group, compared with 40 months in the ADT group (Fig. 2) . Moreover, univariate and multivariate Cox regression analyses showed that RARP (HR 0.264, 95% CI 0.107À0.650; P = 0.004) was an independent prognostic factor for CSS (Table 5 ).
Discussion
The concept of oligometastases was first proposed in 1995 by Hellman and Weichselbaum [19] . Oligometastatic disease, in which there is a limited number of metastatic lesions and/or sites, is thought to be an intermediate state between localized cancer and widespread polymetastases [20, 21] . Although the exact definition of oligometastases is still being debated, most researchers agree that oligometastases and polymetastases are biologically distinct entities. For instance, recent genomic studies have found distinct biological differences between the oligometastatic state and widely disseminated disease for various cancers [21, 22] . Moreover, Uppal et al. [23] reported that several micro-RNAs are differentially expressed between oligometastatic (slow progressors) and polymetastatic (rapid progressors) samples [23] . Similarly, Lussier et al. [24] identified a unique micro-RNA expression signature that can predict the distinct outcomes of patients who maintained stable oligometastatic disease from those who progressed to polymetastases.
The clinical implication of this theory of distinct metastatic states is that local treatment could be effective in patients with oligometastatic cancer. To date, several studies have shown that curative surgical resection of the primary tumour or metastatic lesion improves quality of life and prolongs survival in patients with various metastatic cancers [3] [4] [5] . The rationale for local treatment in metastatic cancer is further supported by studies showing the oncological benefits of tumour debulking and the resulting changes in tumour biology. Surgical resection of the primary tumour could decrease the total tumour burden, thus allowing an improved response to systemic therapies. In addition, removal of the primary source of metastatic cells could alter tumour biology and result in depressed growth, or it could limit the establishment of new metastatic sites [8, 25, 26] .
Although there is a growing interest in the role of RP in oligometastatic PCa, there are no prospective studies on patient survival after RP treatment of oligometastatic PCa, and there are only a few retrospective studies supporting this strategy. Moschini et al. [27] evaluated survival and perioperative outcomes of 47 patients with metastatic PCa (M1a and M1b) treated with surgery or ADT only, and demonstrated the feasibility of local surgical treatment of primary tumour in these patients. They reported cancerspecific mortality-free survival rates at 5 years of 61.9% and 46.2% for patients who underwent surgery and ADT, respectively; however, the difference did not reach statistical significance (P = 0.30). In one case-control study, Heidenreich et al. [7] explored the role of cytoreductive RP in patients with PCa who had low-volume skeletal metastases without visceral or extensive lymph node metastases. They included a total of 61 men (23 RP vs 38 ADT) with lowvolume skeletal metastases (≤3 lesions on bone scan) and response to ADT (PSA nadir <1.0 ng/mL after 6 months of ADT) in their analysis. They identified that time to castration resistance (median 40 vs 29 months; P = 0.014), freedom from clinical progression (median 38.6 vs 26.5 months; 
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© 2017 The Authors BJU International © 2017 BJU International P = 0.032), and overall survival (91.3% vs 78.9%; P = 0.048) were all improved in RP-treated, compared with ADT-treated, patients. In that study cohort, however, all RP-treated patients were responsive to ADT, whereas only 26 of the 38 control, ADT-treated patients were responsive to ADT. It is not clear why the control group was not confined to the 26 ADT responders. Their study is limited by this selection bias.
Moreover, the authors did not show whether RP was an independent prognostic factor for each oncological outcome using multivariate analysis. In another recent study, Gandaglia et al. [8] evaluated peri-operative and long-term oncological outcomes of 11 patients with oligometastatic PCa treated with RP. They defined oligometastatic disease as the presence of five or fewer bone lesions by bone scan, with or without suspicious pelvic or retroperitoneal nodal involvement at preoperative imaging. The 7-year clinical PFS and cancer-specific mortality-free survival rates were 45% and 82%, respectively. Although their data indicate that RP is a safe and feasible option that provides acceptable long-term oncological outcomes in patients with oligometastatic PCa, the small population size limits the generalizability of their findings. Above all, because there is no control group of patients with oligometastatic PCa who underwent an alternative treatment to RP, they could not comprehensively assess the oncological benefits from RP in their study.
To our knowledge, the present study is the first to specifically focus on patients treated with robot-assisted surgery. Importantly, our results suggest that RARP is a safe and feasible treatment option for patients with oligometastatic PCa. The primary benefit of RARP compared with open RP is a decreased risk of bleeding and transfusion [28] . In this regard, it is worth mentioning that the median blood loss and transfusion rate in the present cohort were only 300 mL and 7.9%, respectively. Our postoperative complications (15.4%), readmission (0.0%) and reoperation (2.6%) rates were similar to those previously reported for RP (minimally invasive and open surgery) for standard indications in the meta-analysis (8.2-19.4%, 3.0-11.3%, and 0.9-2.3%, respectively) [29, 30] . Moreover, our postoperative complication rate was consistent Log-rank test, P = 0.002
Time after operation (months) with the overall rate of 12.7% reported for RARP in patients with locally advanced PCa (clinical stage ≥T3) [28] . Finally, a study of the Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2007 showed that~6% of patients had anti-incontinence surgery <2 years after RP; similarly, in the present study there was an overall antiincontinence surgery rate of 7.9%.
The present study also showed that RARP for oligometastatic PCa significantly prevented urinary tract complications. In the control ADT group, 26.8% of the patients had malignant urinary obstruction requiring surgical interventions such as TURP, suprapubic cystostomy, percutaneous nephrostomy and cystoscopic clot evacuation. Conversely, in the RARP group, none of the patients had urinary tract complications as a result of disease progression. Our results are consistent with those from a previous study in which Won et al. [31] reported that BOO requiring TURP in patients with castration-resistant PCa developed in 0%, 15.6% and 22.5% of patients who underwent RP, RT or no local treatment, respectively.
Importantly, in the present study, we showed the survival benefits, in terms of PFS and CSS, of local treatment of the prostate in men diagnosed with oligometastatic PCa. Moreover, our multivariate analyses showed that RARPtreated patients had significantly shorter PFS and CSS compared with ADT-treated patients. These data are an improvement on those from previous studies on RP in the setting of oligometastases, because those studies failed to show multivariate analysis results.
Despite several strengths, the present study has several limitations. First, our data were reviewed retrospectively from a single institution; thus, our results are subject to selection bias, limiting their generalizability. Because of the retrospective nature of the study, we were unable to control patient-and disease-status surrogates such as age, comorbidity, PSA level, biopsy Gleason score and clinical stage. Nevertheless, it is worth noting that we identified RARP as an independent predictor of PFS and CSS using multivariate analyses in the setting of oligometastases where randomized clinical trial data do not currently exist. Second, the impact of additional therapy such as docetaxel, enzalutamide, abiraterone acetate, and palliative RT after cancer progression could not be adjusted in the multivariable analysis, because the patients were treated differently according to their physician's treatment decision. Third, we investigated urinary tract complications in terms of quality of life; however, we did not analyse radiation-induced side effects, such as urinary or fecal incontinence, urinary retention, cystitis and proctitis. Fourth, in this study, high-volume surgeons performed RARP with extended lymph node dissection, limiting our findings regarding safety and feasibility. Lastly, the inclusion of a relatively small population with short-term follow-up might make a difference when comparing oncological outcomes with previous randomized data of patients with low-volume metastatic PCa treated with ADT [32] .
In conclusion, RARP in the setting of oligometastatic PCa is a safe and feasible procedure that improves oncological outcomes in terms of PFS and CSS. In addition, RARP effectively prevents urinary tract complications from PCa. Based on the present results, we believe RARP might be a treatment option in the management of oligometastatic PCa. Nevertheless, the study highlights results from expert surgeons and highly selected patients that cannot be ADT, androgen deprivation therapy; HR, hazard ratio; RARP, robot-assisted radical prostatectomy.
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